{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T10:15:10Z","timestamp":1778667310907,"version":"3.51.4"},"reference-count":118,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Bioeng. Biotechnol."],"abstract":"<jats:p>\n                    Breast cancer\u2013associated malignant pleural effusion (MPE) is a common and debilitating manifestation of advanced disease, yet current management is largely limited to indwelling pleural catheters and chemical pleurodesis and offers only transient palliation without addressing the underlying tumor biology. We propose that integrating patient-derived organoid modeling of pleural tumor cells with characterization via technologies like next-generation sequencing could shift MPE care from symptom management toward precision intervention. Organoid-based drug testing enables\n                    <jats:italic>ex vivo<\/jats:italic>\n                    evaluation of local therapeutic agents, including intrapleural chemotherapy, immune modulators, and bispecific antibodies, while paired genomic profiling may reveal actionable resistance pathways unique to pleural metastases. Together, these approaches could identify rational, localized combination therapies that improve local control, reduce effusion recurrence, and ultimately extend survival. By coupling functional and molecular analyses directly to the pleural compartment, we envision a translational framework that redefines breast MPE from a purely palliative condition to one amenable to mechanism-driven, patient-tailored therapy.\n                  <\/jats:p>","DOI":"10.3389\/fbioe.2026.1750983","type":"journal-article","created":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T09:36:07Z","timestamp":1778664967000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Re-evaluating breast malignant pleural effusion: toward evidence-based, precision-aligned care with organoids"],"prefix":"10.3389","volume":"14","author":[{"given":"Gavin R.","family":"Oliver","sequence":"first","affiliation":[{"name":"Xilis, Inc.","place":["Durham, NC, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kshama","family":"Jaiswal","sequence":"additional","affiliation":[{"name":"University of Utah School of Medicine","place":["Salt Lake City, UT, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W. Roy","family":"Smythe","sequence":"additional","affiliation":[{"name":"Xilis, Inc.","place":["Durham, NC, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlton C.","family":"Barnett","sequence":"additional","affiliation":[{"name":"Xilis, Inc.","place":["Durham, NC, United States"]},{"name":"University of Colorado School of Medicine","place":["Aurora, CO, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1016\/j.ymthe.2018.02.015","article-title":"Phase I study of intrapleural gene-mediated cytotoxic immunotherapy in patients with malignant pleural effusion","volume":"26","author":"Aggarwal","year":"2018","journal-title":"Mol. Ther."},{"key":"B2","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/s41578-020-0199-8","article-title":"Synthetic alternatives to matrigel","volume":"5","author":"Aisenbrey","year":"2020","journal-title":"Nat. Rev. Mater"},{"key":"B3","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1038\/s43018-025-00986-3","article-title":"The tumor microenvironment\u2019s role in the response to immune checkpoint blockade","volume":"6","author":"Aliazis","year":"2025","journal-title":"Nat. Cancer"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1164\/ajrccm.162.5.ats8-00","article-title":"Management of malignant pleural effusions","volume":"162","year":"2000","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"103","DOI":"10.2147\/btt.s6697","article-title":"Palliative treatment of malignant ascites: profile of catumaxomab","volume":"4","author":"Ammouri","year":"2010","journal-title":"Biologics"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1016\/j.athoracsur.2019.08.104","article-title":"Talc pleurodesis: a medical, medicolegal, and socioeconomic review","volume":"109","author":"Baiu","year":"2020","journal-title":"Ann. Thorac. Surg."},{"key":"B7","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s13063-015-0563-y","article-title":"The efficacy of indwelling pleural catheter placement versus placement plus talc sclerosant in patients with malignant pleural effusions managed exclusively as outpatients (IPC-PLUS): study protocol for a randomised controlled trial","volume":"16","author":"Bhatnagar","year":"2015","journal-title":"Trials"},{"key":"B8","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1186\/s12885-016-2935-4","article-title":"Thoracic perfusion of recombinant human endostatin (Endostar) combined with chemotherapeutic agents versus chemotherapeutic agents alone for treating malignant pleural effusions: a systematic evaluation and meta-analysis","volume":"16","author":"Biaoxue","year":"2016","journal-title":"BMC Cancer"},{"key":"B9","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s13665-013-0042-4","article-title":"Advantages of indwelling pleural catheters for management of malignant pleural effusions","volume":"2","author":"Boshuizen","year":"2013","journal-title":"Curr. Respir. Care Rep."},{"key":"B10","doi-asserted-by":"publisher","first-page":"S862","DOI":"10.1016\/j.annonc.2024.08.1426","article-title":"1371P an anti-EpCAM x CD3 bispecific antibody, M701, for the treatment of malignant pleural effusion in NSCLC patients: intermediate results of a prospective multicenter phase Ib trial","volume":"35","author":"Cai","year":"2024","journal-title":"Ann. Oncol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2588","DOI":"10.1200\/jco.2023.41.16_suppl.2588","article-title":"Patient-derived skin MicroOrganoSpheres and clinical response to immunotherapy","volume":"41","author":"Chakraborty","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/s41523-024-00714-7","article-title":"Breast organoid suspension cultures maintain long-term estrogen receptor expression and responsiveness","volume":"10","author":"Chang","year":"2024","journal-title":"NPJ Breast Cancer"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.3760\/cma.j.cn112147-20230902-00126","article-title":"Chinese expert consensus on treatment of malignant pleural effusion","volume":"46","year":"2023","journal-title":"Zhonghua Jie He He Hu Xi Za Zhi"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.4143\/crt.2022.1630","article-title":"Establishment of patient-derived organoids using ascitic or pleural fluid from cancer patients. Cancer Research and treatment","volume":"55","author":"Choi","year":"2023","journal-title":"Official J. Korean Cancer Assoc."},{"key":"B15","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s10549-025-07805-4","article-title":"Palliative care use and end-of-life care quality in HR+\/HER2-metastatic breast cancer","volume":"214","author":"Cohn","year":"2025","journal-title":"Breast Cancer Res. Treat."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1126\/science.1254721","article-title":"Patient-derived models of acquired resistance can identify effective drug combinations for cancer","volume":"346","author":"Crystal","year":"2014","journal-title":"Science"},{"key":"B17","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.biomaterials.2015.09.017","article-title":"3D tissue-engineered bone marrow as a novel model to study pathophysiology and drug resistance in multiple myeloma","volume":"73","author":"de la Puente","year":"2015","journal-title":"Biomaterials"},{"key":"B18","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/j.stem.2022.04.006","article-title":"Patient-derived micro-organospheres enable clinical precision oncology","volume":"29","author":"Ding","year":"","journal-title":"Cell Stem Cell"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2573","DOI":"10.1200\/jco.2022.40.16_suppl.2573","article-title":"Micro-organospheres retain patient tumor microenvironment for precision immuno-oncology","volume":"40","author":"Ding","year":"","journal-title":"J. Clin. Oncol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s40425-019-0590-4","article-title":"Treatment of malignant pleural effusions: the case for localized immunotherapy","volume":"7","author":"Donnenberg","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1157697","DOI":"10.3389\/fimmu.2023.1157697","article-title":"A maladaptive pleural environment suppresses preexisting anti-tumor activity of pleural infiltrating T cells","volume":"14","author":"Donnenberg","year":"2023","journal-title":"Front. Immunol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"3380","DOI":"10.1038\/s41596-020-0379-4","article-title":"Establishment of patient-derived cancer organoids for drug-screening applications","volume":"15","author":"Driehuis","year":"2020","journal-title":"Nat. Protoc."},{"key":"B23","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1200\/OP-24-00925","article-title":"Management of malignant pleural effusion in 2024: a definitive and unified global approach","volume":"21","author":"Duong","year":"2025","journal-title":"JCO Oncol. Pract."},{"key":"B24","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3892\/etm_00000001","article-title":"The angiogenetic pathway in malignant pleural effusions: pathogenetic and therapeutic implications","volume":"1","author":"Economidou","year":"2010","journal-title":"Exp. Ther. Med."},{"key":"B25","first-page":"1175","article-title":"Analysis of the efficacy of endostar thoracic perfusion and DDP intravenous chemotherapy for malignant pleural effusion of breast cancer","volume":"33","author":"Fan","year":"2018","journal-title":"Pract. J. Cancer"},{"key":"B26","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s13045-019-0832-4","article-title":"Emerging organoid models: leaping forward in cancer research","volume":"12","author":"Fan","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1002\/1097-0142(19810415)47:8<2087","article-title":"Pleural effusion in breast cancer: a review of 105 cases","volume":"47","author":"Fentiman","year":"1981","journal-title":"Cancer"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1002\/ijc.35278","article-title":"The GLOBOCAN 2022 cancer estimates: data sources, methods, and a snapshot of the cancer burden worldwide","volume":"156","author":"Filho","year":"2025","journal-title":"Int. J. Cancer"},{"key":"B29","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s40364-022-00356-6","article-title":"Clinical translation of patient-derived tumour organoids-bottlenecks and strategies","volume":"10","author":"Foo","year":"2022","journal-title":"Biomark. Res."},{"key":"B30","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/nrc4015","article-title":"Precision medicine for cancer with next-generation functional diagnostics","volume":"15","author":"Friedman","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"B31","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/s0092-8674(04)00255-7","article-title":"Socializing with the neighbors: stem cells and their niche","volume":"116","author":"Fuchs","year":"2004","journal-title":"Cell"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2025.43.16_suppl.e15518","article-title":"Predicting colorectal cancer patient response to neoadjuvant chemotherapy using the MicroOrganoSphere (MOS) platform","volume":"43","author":"Gobits","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"e2500501","DOI":"10.1200\/PO-25-00501","article-title":"Functional precision medicine using MicroOrganoSpheres for treatment response prediction in advanced colorectal cancer","volume":"10","author":"Gobits","year":"2026","journal-title":"JCO Precis. Oncol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12931-024-02684-7","article-title":"Malignant pleural effusion: current understanding and therapeutic approach","volume":"25","author":"Gonnelli","year":"2024","journal-title":"Respir. Res."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1200\/jco.2023.41.16_suppl.1107","article-title":"Pilot study of a micro-organosphere drug screen platform to lead care in advanced breast cancer (MODEL-ABC)","volume":"41","author":"Graham","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s12912-023-01184-1","article-title":"Depression, anxiety and stress among metastatic breast cancer patients on chemotherapy in China","volume":"22","author":"Guo","year":"2023","journal-title":"BMC Nurs."},{"key":"B37","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1186\/s12905-024-03396-2","article-title":"Prognostic significance of malignant pleural effusions in patients with advanced luminal B breast cancer","volume":"24","author":"Han","year":"2024","journal-title":"BMC Womens Health"},{"key":"B38","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of cancer: new dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov."},{"key":"B39","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1158\/2326-6066.CIR-24-0245","article-title":"Hyperthermic intrathoracic chemotherapy modulates the immune microenvironment of pleural mesothelioma and improves the impact of dual immune checkpoint inhibition","volume":"13","author":"Hao","year":"2025","journal-title":"Cancer Immunol. Res."},{"key":"B40","doi-asserted-by":"publisher","first-page":"359","DOI":"10.3892\/ijo.2021.5174","article-title":"Novel therapies for malignant pleural effusion: anti-angiogenic therapy and immunotherapy","volume":"58","author":"He","year":"2021","journal-title":"Int. J. Oncol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/s41573-021-00301-6","article-title":"Harnessing the predictive power of preclinical models for oncology drug development","volume":"21","author":"Honkala","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1413858","DOI":"10.3389\/fimmu.2024.1413858","article-title":"Application and prospect of organoid technology in breast cancer","volume":"15","author":"Huang","year":"2024","journal-title":"Front. Immunol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"240034","DOI":"10.1183\/20734735.0034-2024","article-title":"Pro: indwelling pleural catheters cause harm to patients","volume":"20","author":"Iqbal","year":"2024","journal-title":"Breathe (Sheff)."},{"key":"B44","doi-asserted-by":"publisher","first-page":"100161","DOI":"10.1016\/j.xcrm.2020.100161","article-title":"An automated organoid platform with inter-organoid homogeneity and inter-patient heterogeneity","volume":"1","author":"Jiang","year":"2020","journal-title":"Cell Rep. Med."},{"key":"B45","doi-asserted-by":"publisher","first-page":"28","DOI":"10.21037\/amj-2019-mpe-05","article-title":"Etiopathogenesis of malignant pleural effusion","volume":"6","author":"Jovanovic","year":"2021","journal-title":"AME Med. J."},{"key":"B46","doi-asserted-by":"publisher","first-page":"17","DOI":"10.4103\/japt.japt_31_24","article-title":"The safety and efficacy of chemical pleurodesis agents in patients with malignant pleural effusion admitted in tertiary care hospital","volume":"8","author":"Kathamuthu","year":"2025","journal-title":"J. Assoc. Pulmonologist Tamil Nadu"},{"key":"B47","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3390\/ph17010045","article-title":"First in vivo applicational data of foam-based intrathoracic chemotherapy (FBiTC) in a swine model","volume":"17","author":"Khosrawipour","year":"2023","journal-title":"Pharm. (Basel)"},{"key":"B48","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.copbio.2003.08.002","article-title":"Role of the extracellular matrix in morphogenesis","volume":"14","author":"Kleinman","year":"2003","journal-title":"Curr. Opin. Biotechnol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1111\/joa.12257","article-title":"Advances in 3D cell culture technologies enabling tissue-like structures to be created in vitro","volume":"227","author":"Knight","year":"2015","journal-title":"J. Anat."},{"key":"B50","doi-asserted-by":"publisher","first-page":"S555","DOI":"10.1016\/j.annonc.2025.08.1394","article-title":"821P functional precision medicine using microorganospheres for treatment response prediction in advanced colorectal cancer","volume":"36","author":"K\u00f6hler","year":"2025","journal-title":"Ann. Oncol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1093\/neurosurgery\/25.cn_suppl_1.346","article-title":"Role of tissue culture in prediction of malignancy","volume":"25","author":"Kornblith","year":"1978","journal-title":"Neurosurgery"},{"key":"B52","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s002620050433","article-title":"Approaches to lung cancer treatment using the CD3 x EGP-2-directed bispecific monoclonal antibody BIS-1","volume":"45","author":"Kroesen","year":"1997","journal-title":"Cancer Immunol. Immunother."},{"key":"B53","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1186\/s12931-024-03023-6","article-title":"Mortality after treatment of malignant pleural effusions with indwelling pleural catheters versus chemical pleurodesis: a population-based study","volume":"25","author":"Kwok","year":"2024","journal-title":"Respir. Res."},{"key":"B54","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jasc.2024.02.005","article-title":"Exploratory pilot study to characterize the immune landscapes of malignant pleural effusions and their corresponding primary tumors from patients with breast carcinoma and lung adenocarcinoma","volume":"13","author":"Laberiano-Fernandez","year":"2024","journal-title":"J. Am. Soc. Cytopathol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1038\/nm.4389","article-title":"Functional precision cancer medicine\u2014moving beyond pure genomics","volume":"23","author":"Letai","year":"2017","journal-title":"News@nat,Com."},{"key":"B56","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ccell.2021.12.004","article-title":"Functional precision oncology: testing tumors with drugs to identify vulnerabilities and novel combinations","volume":"40","author":"Letai","year":"2022","journal-title":"Cancer Cell"},{"key":"B57","doi-asserted-by":"publisher","first-page":"760683","DOI":"10.3389\/fimmu.2021.760683","article-title":"Intrapleural injection of anti-PD1 antibody: a novel management of malignant pleural effusion","volume":"12","author":"Li","year":"2021","journal-title":"Front. Immunol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1186\/s12967-025-06349-x","article-title":"Reproducible extracellular matrices for tumor organoid culture: challenges and opportunities","volume":"23","author":"Li","year":"2025","journal-title":"J. Transl. Med."},{"key":"B59","doi-asserted-by":"publisher","first-page":"9390912","DOI":"10.1155\/2022\/9390912","article-title":"Combining organoid models with next-generation sequencing to reveal tumor heterogeneity and predict therapeutic response in breast cancer","volume":"2022","author":"Liu","year":"2022","journal-title":"J. Oncol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"e172419","DOI":"10.1172\/jci.insight.172419","article-title":"The effect of extracellular matrix on the precision medicine utility of pancreatic cancer patient-derived organoids","volume":"9","author":"Lumibao","year":"2024","journal-title":"JCI Insight"},{"key":"B61","first-page":"114","article-title":"Lost in translation: animal models and clinical trials in cancer treatment","volume":"6","author":"Mak","year":"2014","journal-title":"Am. J. Transl. Res."},{"key":"B62","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1186\/s12890-023-02530-4","article-title":"Management of malignant pleural effusion in Italian clinical practice: a nationwide survey","volume":"23","author":"Mei","year":"2023","journal-title":"BMC Pulm. Med."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1136\/thorax-2022-219449","article-title":"Patient perspectives on the use of indwelling pleural catheters in malignant pleural effusions","volume":"78","author":"Mitchell","year":"2023","journal-title":"Thorax"},{"key":"B64","doi-asserted-by":"publisher","first-page":"9538","DOI":"10.7150\/thno.55954","article-title":"Benefits of functional assays in personalized cancer medicine: more than just a proof-of-concept","volume":"11","author":"Morand du Puch","year":"2021","journal-title":"Theranostics"},{"key":"B65","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1200\/OP.24.00387","article-title":"Current trends in treating malignant pleural effusion: evidence, guidelines, and best practice recommendations","volume":"21","author":"Munavvar","year":"2025","journal-title":"JCO Oncol. Pract."},{"key":"B66","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1111\/crj.13010","article-title":"Intrapleural immunotherapy: an update on emerging treatment strategies for pleural malignancy","volume":"13","author":"Murthy","year":"2019","journal-title":"Clin. Respir. J."},{"key":"B67","doi-asserted-by":"publisher","first-page":"912641","DOI":"10.3389\/fmed.2022.912641","article-title":"Functional drug screening in the era of precision medicine","volume":"9","author":"Napoli","year":"2022","journal-title":"Front. Med. (Lausanne)"},{"key":"B68","unstructured":"NIH animal model funding\n          \n          \n          2023"},{"key":"B69","volume-title":"NIH establishes nation\u2019s first dedicated organoid development center to reduce reliance on animal modeling","year":"2024"},{"key":"B70","doi-asserted-by":"publisher","first-page":"3602","DOI":"10.3390\/cancers15143602","article-title":"Advancing cancer therapy predictions with patient-derived organoid models of metastatic breast cancer","volume":"15","author":"\u00d6nder","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B71","doi-asserted-by":"publisher","first-page":"6867","DOI":"10.3390\/curroncol31110507","article-title":"Malignant pleural effusion: diagnosis and treatment-up-to-date perspective","volume":"31","author":"Orlandi","year":"2024","journal-title":"Curr. Oncol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1007\/s11626-021-00563-9","article-title":"Breast cancer organoids from malignant pleural effusion-derived tumor cells as an individualized medicine platform","volume":"57","author":"Pan","year":"2021","journal-title":"Vitro Cell Dev. Biol. Anim."},{"key":"B73","doi-asserted-by":"publisher","first-page":"100045","DOI":"10.1016\/j.soi.2024.100045","article-title":"Intra-pleural and intra-peritoneal tocilizumab therapy for managing malignant pleural effusions and ascites: the Regional Immuno-Oncology Trial (RIOT)\u22122 study protocol","volume":"1","author":"Park","year":"2024","journal-title":"Surg. Oncol. Insight"},{"key":"B74","doi-asserted-by":"publisher","first-page":"e41689","DOI":"10.7759\/cureus.41689","article-title":"The psychosocial impact of Indwelling Pleural Catheters: a scoping review","volume":"15","author":"Peel","year":"2023","journal-title":"Cureus"},{"key":"B75","doi-asserted-by":"publisher","first-page":"229","DOI":"10.2147\/CMAR.S95663","article-title":"Management of malignant pleural effusion: challenges and solutions","volume":"9","author":"Penz","year":"2017","journal-title":"Cancer Manag. Res."},{"key":"B76","doi-asserted-by":"publisher","first-page":"9064","DOI":"10.1073\/pnas.89.19.9064","article-title":"Interaction with basement membrane serves to rapidly distinguish growth and differentiation pattern of normal and malignant human breast epithelial cells","volume":"89","author":"Petersen","year":"1992","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B77","doi-asserted-by":"publisher","first-page":"230145","DOI":"10.1183\/20734735.0145-2023","article-title":"Malignant pleural disease","volume":"19","author":"Piggott","year":"2023","journal-title":"Breathe (Sheff)"},{"key":"B78","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1242\/jcs.188102","article-title":"Comparison of cancer cells in 2D vs 3D culture reveals differences in AKT-mTOR-S6K signaling and drug responses","volume":"130","author":"Riedl","year":"2017","journal-title":"J. Cell Sci."},{"key":"B79","doi-asserted-by":"publisher","first-page":"1600505","DOI":"10.1002\/biot.201600505","article-title":"Drug screening in 3D in vitro tumor models: overcoming current pitfalls of efficacy read-outs","volume":"12","author":"Santo","year":"2017","journal-title":"Biotechnol. J."},{"key":"B80","doi-asserted-by":"publisher","first-page":"4584","DOI":"10.1002\/cncr.33137","article-title":"Quality of care at safety-net hospitals and the impact on pay-for-performance reimbursement","volume":"126","author":"Sarkar","year":"2020","journal-title":"Cancer"},{"key":"B81","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1097\/CJI.0b013e318195b5bb","article-title":"Treatment of malignant pleural effusion with the trifunctional antibody catumaxomab (Removab) (anti-EpCAM x Anti-CD3): results of a phase 1\/2 study","volume":"32","author":"Sebastian","year":"2009","journal-title":"J. Immunother."},{"key":"B82","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.3390\/cancers17132143","article-title":"The evolving role of chemotherapy in the management of pleural malignancies: current evidence and future directions","volume":"17","author":"Semenova","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B83","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1097\/LBR.0000000000000192","article-title":"Management of malignant pleural effusion","volume":"22","author":"Shafiq","year":"2015","journal-title":"J. Bronchology Interv. Pulmonol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1111\/imj.16366","article-title":"Management of malignant pleural effusion and trapped lung: a survey of respiratory physicians and thoracic surgeons in Australasia","volume":"54","author":"Sidhu","year":"2024","journal-title":"Intern Med. J."},{"key":"B85","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1089\/jpm.2022.0592","article-title":"Cost comparison of treatment alternatives for pleural effusion and ascites from a payer perspective: are there cost savings from indwelling catheters?","volume":"26","author":"Siefen","year":"2023","journal-title":"J. Palliat. Med."},{"key":"B86","doi-asserted-by":"publisher","first-page":"210","DOI":"10.3390\/jor4040019","article-title":"The 2023 British Thoracic Society guideline for pleural disease update on malignant pleural effusion","volume":"4","author":"Sivabalah","year":"2024","journal-title":"JoR"},{"key":"B87","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1309\/AJCPYO5FSV3UPEXS","article-title":"Breast cancer subtypes predispose the site of distant metastases","volume":"143","author":"Soni","year":"2015","journal-title":"Am. J. Clin. Pathol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"672","DOI":"10.4236\/jct.2014.57076","article-title":"Cancer chemosensitivity testing: review","volume":"5","author":"Su","year":"2014","journal-title":"J. Cancer Ther."},{"key":"B89","doi-asserted-by":"publisher","first-page":"102226","DOI":"10.1016\/j.tranon.2024.102226","article-title":"Patient-derived tumor organoids: a preclinical platform for personalized cancer therapy","volume":"51","author":"Taurin","year":"2025","journal-title":"Transl. Oncol."},{"key":"B90","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1111\/resp.12328","article-title":"Interventional therapies for malignant pleural effusions: the present and the future: interventions for MPE","volume":"19","author":"Thomas","year":"2014","journal-title":"Respirology"},{"key":"B91","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1038\/s12276-024-01272-5","article-title":"Patient-derived tumor organoids: a new avenue for preclinical research and precision medicine in oncology","volume":"56","author":"Thorel","year":"2024","journal-title":"Exp. Mol. Med."},{"key":"B92","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/j.medj.2024.08.010","article-title":"Patient-derived organoids in precision cancer medicine","volume":"5","author":"Tong","year":"2024","journal-title":"Med. (N Y)"},{"key":"B93","doi-asserted-by":"publisher","first-page":"115803","DOI":"10.1016\/j.bcp.2023.115803","article-title":"Breast cancer organoids derived from patients: a platform for tailored drug screening","volume":"217","author":"Tzeng","year":"2023","journal-title":"Biochem. Pharmacol."},{"key":"B94","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1007\/s11136-025-03914-1","article-title":"Long-term health-related quality of life among adolescent and young adult breast cancer survivors","volume":"34","author":"Vrancken Peeters","year":"2025","journal-title":"Qual. Life Res."},{"key":"B95","doi-asserted-by":"publisher","first-page":"649999","DOI":"10.3389\/fonc.2021.649999","article-title":"Intrapleural administration with Rh-endostatin and chemical irritants in the control of malignant pleural effusion: a systematic review and meta-analysis","volume":"11","author":"Wang","year":"2021","journal-title":"Front. Oncol."},{"key":"B96","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1016\/j.stemcr.2022.07.016","article-title":"Rapid tissue prototyping with micro-organospheres","volume":"17","author":"Wang","year":"2022","journal-title":"Stem Cell Rep."},{"key":"B97","doi-asserted-by":"publisher","first-page":"409","DOI":"10.2147\/CMAR.S409918","article-title":"A novel clinical prognostic model for breast cancer patients with malignant pleural effusion: avoiding chemotherapy in low-risk groups?","volume":"15","author":"Wang","year":"","journal-title":"Cancer Manag. Res."},{"key":"B98","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1111\/cts.13430","article-title":"Incidence of complications from indwelling pleural catheter for pleural effusion: a meta-analysis","volume":"16","author":"Wang","year":"","journal-title":"Clin. Transl. Sci."},{"key":"B99","doi-asserted-by":"publisher","first-page":"11149","DOI":"10.1002\/cam4.5698","article-title":"Role of tumor microenvironment in cancer progression and therapeutic strategy","volume":"12","author":"Wang","year":"","journal-title":"Cancer Med."},{"key":"B100","doi-asserted-by":"publisher","first-page":"432","DOI":"10.4236\/jct.2024.1512038","article-title":"The observation of clinical efficacy and safety of de-platinum-based pleural perfusion in the treatment of malignant pleural effusion and its correlation with the expression of VEGF in pleural fluid","volume":"15","author":"Wang","year":"","journal-title":"J. Cancer Ther."},{"key":"B101","doi-asserted-by":"publisher","first-page":"694","DOI":"10.4103\/ijc.IJC_1065_20","article-title":"Safety of Endostar in combination with chemotherapy in patients with cancer","volume":"61","author":"Wang","year":"","journal-title":"Indian J. Cancer"},{"key":"B102","first-page":"615","article-title":"Clonogenic and nonclonogenic in vitro chemosensitivity assays","volume":"69","author":"Weisenthal","year":"1985","journal-title":"Cancer Treat. Rep."},{"key":"B103","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41698-021-00168-1","article-title":"Patient-derived organoids as a predictive biomarker for treatment response in cancer patients","volume":"5","author":"Wensink","year":"2021","journal-title":"NPJ Precis. Oncol."},{"key":"B104","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/bs.pmbts.2017.07.002","article-title":"Breast cancer epidemiology, prevention, and screening","volume":"151","author":"Winters","year":"2017","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"B105","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1055\/s-0043-1769092","article-title":"Malignant pleural effusions in the era of immunotherapy and antiangiogenic therapy","volume":"44","author":"Wong","year":"2023","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"B106","doi-asserted-by":"publisher","first-page":"8047","DOI":"10.1200\/jco.2023.41.16_suppl.8047","article-title":"Patient-derived MicroOrganoSpheres (MOS) and precision clinical decision-making for patients with multiple myeloma","volume":"41","author":"Xi","year":"","journal-title":"J. Clin. Oncol."},{"key":"B107","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1158\/1538-7445.am2023-3412","article-title":"Abstract 3412: Patient-derived MicroOrganoSpheres (MOS) enable precision clinical decision-making for multiple myeloma patients","volume":"83","author":"Xi","year":"","journal-title":"Cancer Res."},{"key":"B108","doi-asserted-by":"publisher","first-page":"3300","DOI":"10.7150\/thno.96027","article-title":"Building consensus on the application of organoid-based drug sensitivity testing in cancer precision medicine and drug development","volume":"14","author":"Xiang","year":"2024","journal-title":"Theranostics"},{"key":"B109","doi-asserted-by":"publisher","first-page":"e080703","DOI":"10.1136\/bmjopen-2023-080703","article-title":"Thoracic perfusion of antiangiogenic agents combined with chemotherapy for treating malignant pleural effusion in non-small cell lung cancer: a network meta-analysis","volume":"14","author":"Xu","year":"2024","journal-title":"BMJ Open"},{"key":"B110","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1002\/cncy.22205","article-title":"Targeted deep sequencing of cell-free DNA in serous body cavity fluids with malignant, suspicious, and benign cytology","volume":"128","author":"Yang","year":"2020","journal-title":"Cancer Cytopathol."},{"key":"B111","doi-asserted-by":"publisher","first-page":"lnae016","DOI":"10.1093\/lifemedi\/lnae016","article-title":"Bridging the organoid translational gap: integrating standardization and micropatterning for drug screening in clinical and pharmaceutical medicine","volume":"3","author":"Yang","year":"2024","journal-title":"Life Med."},{"key":"B112","doi-asserted-by":"publisher","first-page":"32","DOI":"10.20517\/cdr.2025.34","article-title":"Modeling methods of different tumor organoids and their application in tumor drug resistance research","volume":"8","author":"Yang","year":"2025","journal-title":"Canc Drug Resist"},{"key":"B113","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12890-015-0025-z","article-title":"Important prognostic factors for survival in patients with malignant pleural effusion","volume":"15","author":"Zamboni","year":"2015","journal-title":"BMC Pulm. Med."},{"key":"B114","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/s0885-3924(02)00497-9","article-title":"Cancer pain and psychosocial factors: a critical review of the literature","volume":"24","author":"Zaza","year":"2002","journal-title":"J. Pain Symptom Manage"},{"key":"B115","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s13019-021-01475-1","article-title":"Complications of thoracoscopic talc insufflation for the treatment of malignant pleural effusions: a meta-analysis","volume":"16","author":"Zhang","year":"2021","journal-title":"J. Cardiothorac. Surg."},{"key":"B116","doi-asserted-by":"crossref","DOI":"10.1136\/thorax-2023-BTSabstracts.144","article-title":"S138 Malignant pleural effusions: evaluating the psychosocial impact of indwelling pleural catheters on patients (MY-IPC) \u2013 an interim analysis","volume-title":"Bridge over troubled waters\u2019 \u2013 managing the exudative effusion","author":"Zhang","year":"2023"},{"key":"B117","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s43586-022-00174-y","article-title":"Organoids","volume":"2","author":"Zhao","year":"2022","journal-title":"Nat. Rev. Methods Prim."},{"key":"B118","doi-asserted-by":"publisher","first-page":"14375","DOI":"10.1002\/cam4.5943","article-title":"Standardization of organoid culture in cancer research","volume":"12","author":"Zhou","year":"2023","journal-title":"Cancer Med."}],"container-title":["Frontiers in Bioengineering and Biotechnology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fbioe.2026.1750983\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T09:36:19Z","timestamp":1778664979000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fbioe.2026.1750983\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,13]]},"references-count":118,"alternative-id":["10.3389\/fbioe.2026.1750983"],"URL":"https:\/\/doi.org\/10.3389\/fbioe.2026.1750983","relation":{},"ISSN":["2296-4185"],"issn-type":[{"value":"2296-4185","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,13]]},"article-number":"1750983"}}